Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study
Abstract
The objective of the study is to evaluate the effectiveness and tolerability of atomoxetine in youth, ages 6-17 years with ADHD, who had a prior trial of stimulant treatment. This was a 6-week prospective open-label study of atomoxetine, dosage up to 1.4 mg/kg per day in 34 children and adolescents with DSM-IV ADHD. Primary measures of response included the ADHD Rating Scale (ADHD RS) and the Clinical Global Impression (CGI) Scale. Analyses were intention-to-treat. The treatment with atomoxetine was associated with statistical and clinical significant reduction in clinician rated ADHD RS symptoms, compared with baseline. Statistical significant improvement was attained by the second week of treatment. Fifty-six percent (N = 18) met criteria for our a priori definition of response; much or very much improved on the CGI plus more than 30% reduction in ADHD RS symptoms. In conclusion, atomoxetine was generally well tolerated; 85% of subjects completed the trial. Atomoxetine was effective and well tolerated in a 6-week open study of ADHD youth with a prior history of stimulant treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Atomoxetine efficacy has been confirmed in populations around the world, including for children with oppositional defiant disorder or those who have received previous stimulant therapy.
“studies in populations around the world have continued to confirm its efficacy [78-81], including for children with oppositional defiant disorder [82] or those who have received previous stimulant therapy [83].”
From Advances in understanding and treating ADHD (2011) · cites this paper as [83]
Cites
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982 · see citing works
BIEDERMAN, J., MONUTEAUX, M. C., MICK, E., SPENCER, T., WILENS, T. E., SILVA, J. M., SNYDER, L. E., & FARAONE, S. V. (2006) · Psychological Medicine · doi:10.1017/s0033291705006410 · Cited by 850 · see citing works
Self-citationMichelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · see citing works
Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336 · see citing works
Attention-Deficit/Hyperactivity Disorder: Diagnosis, Lifespan, Comorbidities, and Neurobiology
Spencer, T. J., Biederman, J., & Mick, E. O. (2007) · Ambulatory Pediatrics · doi:10.1016/j.ambp.2006.07.006 · Cited by 277 · see citing works
Self-citationBiederman, J., Monuteaux, M. C., Mick, E. O., Spencer, T. J., Wilens, T. E., Klein, K. L., Price, J., & Faraone, S. V. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.031 · Cited by 168 · see citing works
Self-citationKRATOCHVIL, C. J., WILENS, T. E., GREENHILL, L. L., GAO, H., BAKER, K. D., FELDMAN, P. D., & GELOWITZ, D. L. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000222788.34229.68 · Cited by 150 · see citing works
Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder
Wilens, T. E., Newcorn, J. H., Kratochvil, C. J., Gao, H., Thomason, C. K., Rogers, A. K., Feldman, P. D., & Levine, L. R. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.01.052 · Cited by 102 · cited 1× · see citing works
“Since approval, atomoxetine has demonstrated short- and long-term efficacy in children and adolescents [5, 9, 13, 16, 17 ], however, there has been limited study of atomoxetine’s effectiveness and tolerability in children selected according to a history of stimulant exposure (Quintana et al. [14]).”
BackgroundBuitelaar, J. K., Danckaerts, M., Gillberg, C., Zuddas, A., Becker, K., Bouvard, M. P., Fagan, J., Gádoros, J., Harpin, V., Hazell, P., et al. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-0401-3 · Cited by 76 · see citing works
Kratochvil, C. J., Milton, D. R., Vaughan, B. S., & Greenhill, L. L. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-25 · Cited by 64 · see citing works
Do Children and Adolescents With ADHD Respond Differently to Atomoxetine?
Wilens, T. E., Kratochvil, C., Newcorn, J. H., & Gao, H. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000190352.90946.0b · Cited by 59 · see citing works
Low-Dose Atomoxetine for Maintenance Treatment of Attention-Deficit/Hyperactivity Disorder
Newcorn, J. H., Michelson, D., Kratochvil, C. J., Allen, A. J., Ruff, D. D., Moore, R. J., & for the Atomoxetine Low-dose Study Group (2006) · PEDIATRICS · doi:10.1542/peds.2005-2999 · Cited by 34 · see citing works
Quintana, H., Cherlin, E. A., Duesenberg, D. A., Bangs, M. E., Ramsey, J. L., Feldman, P. D., Allen, A. J., & Kelsey, D. K. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.017 · Cited by 34 · see citing works
Bakken, R., Paczkowski, M., Kramer, H. P., Axelson, A. A., Williams, D. W., Malcolm, S. K., Sumner, C. R., & Kelsey, D. K. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253627 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Advances in understanding and treating ADHD
Antshel, K. M., Hargrave, T. M., Simonescu, M., Kaul, P., Hendricks, K., & Faraone, S. V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-72 · Cited by 140 · see citing works
- Authors
- Hammerness, P., Doyle, R., Kotarski, M., Georgiopoulos, A., Joshi, G., Zeitlin, S., & Biederman, J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Hammerness, Paul
- Venue
- European Child & Adolescent Psychiatry
- Published
- 2009-04-18
- Volume
- 18
- Issue
- 8
- Pages
- 493-498
- ISSN
- 1018-8827 (ISSN-L)
- 1435-165X
- OpenAlex
- W2033673747
- Cited by
- 8
- References
- 14
- Citations by year
- 2016: 1 · 2015: 1 · 2014: 1 · 2012: 1
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, children and adolescents, treatment response, tolerability, ADHD Rating Scale, Clinical Global Impression Scale, non-stimulant medication
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Analysis of Variance, Attention Deficit Disorder with Hyperactivity, Child, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Propylamines, Prospective Studies, Chi-Square Distribution, Treatment Outcome, Patient Satisfaction, Patient Selection, Adrenergic Uptake Inhibitors, Diagnostic and Statistical Manual of Mental Disorders, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
